Product and business development teams at biotechnology firms are increasingly using AI to scope new digital sequence information programmes, draft partnership term sheets for high-seas marine genetic resource projects, and generate licensing-template language that anchors to the correct provision of the BBNJ Agreement.
The RLB Specialist Panel put a set of practitioner-grade questions on the BBNJ Agreement to two frontier AI models with web search active.
Each question is prepared by the Panel based on the workflows that product & business development teams at biotechnology firms actually use AI for under this treaty, covering the screening threshold for environmental impact assessments under Part IV, the temporal scope of the marine genetic resources and digital sequence information regime under Part II, the benefit-sharing duty for digital sequence information, and the non-undermining duty constraining Conference of the Parties decisions on area-based management tools under Part III.
The Panel then binds every AI response to verbatim regulator-issued source text held as primary substrate, comparing the AI output line-by-line against the deposited treaty text. Only responses where the AI subject was demonstrably wrong against the verbatim regulator-issued source text are published; responses that were substantively correct, or that refused on calibration grounds, are retained internally and not surfaced. On the BBNJ Agreement, the AI subjects returned a single hallucinated answer in the form of Source-Credit Misattribution for product & business development teams at biotechnology firms.
For product and business development teams at biotechnology firms scoping programmes that touch high-seas marine genetic resources or digital sequence information, citation accuracy in term sheets, licensing templates, and partnership scoping documents shapes downstream commercial terms. A go-to-market scope anchored to the wrong article reference under the {REG_SHORT} is brittle: the substantive position may be salvageable, but the citation will need to be reworked, and downstream collateral, including counterparty memos and external pitches, may need to be revised mid-flight.
The published Specialist Panel findings, with model attribution, carry the following citation identifiers, each hyperlinked to the bound regulator-issued source text on the BBNJ Agreement regulation hub. The audit register surfaces these findings for product & business development teams at biotechnology firms so that any AI-assisted treaty citation, paraphrase, or rule-statement entering a deliverable can be re-validated against the deposited treaty text before the document is issued:
RLB-H-INT-UNTC-BBNJ-HIGH-SEAS-BIODIVERSITY-AGREEMENT-2023-Q004-Sonnet46 (DSI benefit-sharing article misidentified)This is the consolidated view of findings. Click the Citation IDs or 'see details →' on any item for the full details for each finding.
A product or business development team at a biotechnology firm scoping a digital sequence information programme - whether an internal data-handling workflow, a partnership term sheet, or a licensing template - would, on this AI response, build the framework around Article 15(5) as the controlling provision. Article 14(1) is the controlling provision. A go-to-market scope anchored to the wrong article reference is brittle: the substantive position is salvageable but the citation will need to be reworked, and downstream collateral may need to be revised.
Every finding on this page compares an AI subject's account of the rule against the regulator's verbatim text from the regulator's own portal. Both are linked. Each delta, its root causes, and impact analysis are documented and published with immutable Citation IDs.